Retatrutide Delivers 18.8% Weight Loss in Type 2 Diabetes at 80 Weeks
TRIUMPH-2 shows that a triple GIP, GLP-1, and glucagon receptor agonist can push weight loss in obesity with type 2 diabetes past the 15% ceiling seen with prior agents, with dose-dependent tolerability signals that pharmacists should anticipate.
📅 Journal publication: Oct 10, 2026(online Sep 29, 2026)·Last updated: Nov 20, 2026
In TRIUMPH-2, retatrutide 12 mg cut body weight 18.8% over 80 weeks in adults with type 2 diabetes, versus 5.1% on placebo.
Obesity and type 2 diabetes are closely linked, and effective treatments are needed to manage both conditions simultaneously. Retatrutide 12 mg reduced bodyweight by 18.8% compared to 5.1% with placebo. All doses improved glycemic control. Retatrutide shows promise for obesity and diabetes management, but gastrointestinal side effects and higher discontinuation rates may limit its use. Retatrutide significantly reduces bodyweight and improves glycemic control but requires monitoring for gastrointestinal side effects.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A
Citation:Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1